-
Tytuł:
-
A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis.
-
Autorzy:
-
Bechman K; Centre of Rheumatic Diseases, Weston Education Centre, King's College London, Room 3.46, Third Floor, London, SE5 9RJ, UK. .
Dalrymple A; Centre of Rheumatic Diseases, Weston Education Centre, King's College London, Room 3.46, Third Floor, London, SE5 9RJ, UK.
Southey-Bassols C; Centre of Rheumatic Diseases, Weston Education Centre, King's College London, Room 3.46, Third Floor, London, SE5 9RJ, UK.
Cope AP; Centre of Rheumatic Diseases, Weston Education Centre, King's College London, Room 3.46, Third Floor, London, SE5 9RJ, UK.
Galloway JB; Centre of Rheumatic Diseases, Weston Education Centre, King's College London, Room 3.46, Third Floor, London, SE5 9RJ, UK.
-
Źródło:
-
BMC rheumatology [BMC Rheumatol] 2020 Nov 02; Vol. 4 (1), pp. 70. Date of Electronic Publication: 2020 Nov 02.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [London] : BioMed Central Ltd., [2017]-
-
References:
-
Arthritis Res Ther. 2014 Apr 25;16(2):R103. (PMID: 24766912)
Arthritis Rheum. 2000 Jan;43(1):155-63. (PMID: 10643712)
Arthritis Rheum. 2004 Mar;50(3):709-15. (PMID: 15022309)
Arthritis Res Ther. 2014 Oct 30;16(5):467. (PMID: 25359150)
Arthritis Rheum. 2007 Oct;56(10):3271-83. (PMID: 17907173)
Arthritis Res Ther. 2012 Feb 15;14(1):R34. (PMID: 22336440)
N Engl J Med. 2004 Jun 17;350(25):2572-81. (PMID: 15201414)
Arthritis Res Ther. 2015 Sep 19;17:260. (PMID: 26385705)
Arthritis Res Ther. 2014 Sep 24;16(5):434. (PMID: 25249397)
JAMA. 1999 Dec 8;282(22):2131-5. (PMID: 10591334)
Ann Rheum Dis. 2007 Sep;66(9):1221-6. (PMID: 17369281)
Am J Med. 1997 Dec 29;103(6A):12S-18S. (PMID: 9455964)
PLoS One. 2017 Sep 8;12(9):e0182927. (PMID: 28886017)
Arthritis Res Ther. 2009;11(1):207. (PMID: 19232067)
Rheumatology (Oxford). 2011 Mar;50(3):603-10. (PMID: 21098574)
J Immunol. 2001 Aug 15;167(4):1920-8. (PMID: 11489971)
Lancet. 2016 Oct 22;388(10055):2023-2038. (PMID: 27156434)
Arthritis Rheum. 2011 May;63(5):1265-73. (PMID: 21305530)
Arthritis Rheum. 2013 Sep;65(9):2253-61. (PMID: 23740460)
PLoS Med. 2009 Jan 13;6(1):e1. (PMID: 19143467)
Arthritis Res Ther. 2014;16(2):R90. (PMID: 25167216)
Arthritis Res Ther. 2017 Feb 2;19(1):20. (PMID: 28148302)
Ann Rheum Dis. 2005 Dec;64(12):1731-6. (PMID: 15878904)
Rheumatology (Oxford). 2014 Oct;53(10):1886-95. (PMID: 24764267)
Arthritis Res Ther. 2018 Jun 7;20(1):114. (PMID: 29880013)
Arthritis Res Ther. 2012 Jan 08;14(1):R6. (PMID: 22225620)
Arthritis Res Ther. 2016 Apr 22;18:93. (PMID: 27102921)
Arthritis Rheum. 2004 Jun;50(6):1761-9. (PMID: 15188351)
Ann Rheum Dis. 2015 Jun;74(6):1311-6. (PMID: 25398374)
-
Grant Information:
-
MR/R001332/1 United Kingdom MRC_ Medical Research Council; CTRF- MR/R001332/1 United Kingdom MRC_ Medical Research Council
-
Entry Date(s):
-
Date Created: 20201209 Latest Revision: 20240214
-
Update Code:
-
20240214
-
PubMed Central ID:
-
PMC7604968
-
DOI:
-
10.1186/s41927-020-00154-3
-
PMID:
-
33292827
-
Background: The B cell chemoattractant CXCL13 is a promising biomarker in rheumatoid arthritis (RA), with a plausible role in supporting diagnosis, monitoring disease activity and as a prognostic value. It is a key chemokine driving the formation of lymphoid follicles within the inflamed synovium. The objective of this systematic review was to evaluate the role of CXCL13 as a viable biomarker in RA.
Methods: We conducted a systematic literature review of all published cohort and randomised controlled trials evaluating the role of CXCL13 in RA. The primary outcomes were; i) CXCL13 levels in RA patients compared to healthy controls, ii) the correlation between CXCL13 and markers of disease activity, and iii) the association between CXCL13 and treatment response.
Results: The search produced 278 articles, of which 31 met the inclusion criteria. Of the 12 studies evaluating CXCL13 expression in early or established RA, all reported higher levels than that seen in healthy controls. Twelve of sixteen studies reported a weakly positive correlation between CXCL13 and markers of disease activity including DAS28 and swollen joint count, with rho values between 0.20-0.67. In 2 studies, CXCL13 levels correlated with ultrasonographic evidence of synovitis. Eighteen studies assessed CXCL13 in response to therapeutic intervention. The majority signified a fall in levels in response to treatment including biologics and Janus kinase (JAK) inhibition. In some, this reduction was only seen in treatment responders. High CXCL13 levels predicted failure to achieve disease remission with csDMARDs. The evidence for treatment prediction with biologics was conflicting.
Conclusion: Despite evidence to suggest a role in diagnosing RA and in detecting synovitis, the heterogeneity of studies included in this review limit our ability to draw robust conclusions. At present there are inadequate results to justify the routine use of CXCL13 as a biomarker in RA routine clinical practice.
